Sight Sciences reports Q4 EPS (23c), consensus (18c)

Reports Q4 revenue $19.1M, consensus $19M.”As we turn to 2025, we are focused on advancing our strategic initiatives, which include building commercial momentum in MIGS through a continued commitment to education and engagement with our customers, establishing equitable reimbursement for TearCare, and publishing new clinical and cost data to support the adoption and use of our portfolio of interventional technologies,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences (SGHT). “While the MIGS market has been in flux for the last eighteen months, we believe the comprehensive procedure performed with OMNI, which is supported by our strong commercial presence, will continue to be a market-leading choice for surgeons treating their glaucoma patients. We are also excited about the TearCare market access opportunity for the millions of patients suffering from dry eye disease and our robust pipeline of interventional glaucoma and dry eye technologies, including an upcoming next generation OMNI release expected in the first half of 2025.”